IMWG MRD criteria
| Response . | Criteria . |
|---|---|
| Sustained MRD negative | MRD negativity in the marrow (NGF or NGS, or both) and by imaging (PET CT), confirmed minimum of 1 year apart. Subsequent evaluations can be used to further specify the duration of negativity (eg, MRD negative at 5 years). |
| Flow MRD negative | Absence of phenotypically aberrant clonal plasma cells by NGF on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 105 nucleated cells or higher. |
| Sequencing MRD negative | Absence of clonal plasma cells by NGS on bone marrow aspirate in which the presence of a clone is defined as fewer than 2 identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 105 nucleated cells or higher. |
| Imaging plus MRD negative | MRD negativity as defined by NGF or NGS plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET CT or decrease to less than mediastinal blood pool SUV or decrease to less than that of surrounding normal tissue. |
| Response . | Criteria . |
|---|---|
| Sustained MRD negative | MRD negativity in the marrow (NGF or NGS, or both) and by imaging (PET CT), confirmed minimum of 1 year apart. Subsequent evaluations can be used to further specify the duration of negativity (eg, MRD negative at 5 years). |
| Flow MRD negative | Absence of phenotypically aberrant clonal plasma cells by NGF on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 105 nucleated cells or higher. |
| Sequencing MRD negative | Absence of clonal plasma cells by NGS on bone marrow aspirate in which the presence of a clone is defined as fewer than 2 identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 105 nucleated cells or higher. |
| Imaging plus MRD negative | MRD negativity as defined by NGF or NGS plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET CT or decrease to less than mediastinal blood pool SUV or decrease to less than that of surrounding normal tissue. |
Table adapted from Kumar et al.9
SUV, standard uptake value.